Anlotinib plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: A prospective, single-arm, single-center, phase II clinical study

被引：1
|
作者：
Chen, X. [1 ]
Zhang, S. [1 ]
Li, X. [2 ]
Zhang, Y. [1 ]
Li, Y. [2 ]
Kang, H. [1 ]
Guan, H. [1 ]
She, Q. [2 ]
Ma, X. B. [1 ]
Diao, Y. [1 ]
Liu, D. [1 ]
Min, W. [1 ]
Liu, M. [1 ]
Wu, F. [1 ]
Feng, C. [1 ]
机构：
[1] Xi An Jiao Tong Univ, Affiliated Hosp 2, Oncol, Xian, Peoples R China
[2] Baoji Cent Hosp, Oncol, Baoji, Shaanxi, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.450
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
169P
引用
收藏
页码：S433 / S433
页数：1
相关论文
共 50 条
  • [41] Single arm study of neoadjuvant chemotherapy without taxane for BRCAness cases in triple-negative breast cancer
    Ishikawa, Takashi
    Teraoka, Saeko
    Kaise, Hiroshi
    Yamada, Kimito
    Hosonaga, Man
    Ueda, Ai
    Kawai, Yoko
    Okazaki, Miki
    Oba, Mari S.
    Sato, Eiichi
    CANCER RESEARCH, 2016, 76
  • [42] A phase 2, open-label, single-arm, multi-center study of talazoparib for neoadjuvant treatment of germline BRCA1/2 mutation patients with early-stage triple-negative breast cancer (TNBC)
    Litton, J.
    Symmans, F.
    Gogineni, K.
    Saltzman, M.
    Telli, M. L.
    Usha, L.
    Chakrabarti, J.
    Tudor, I. C.
    Quek, R. G.
    Czibere, A.
    CANCER RESEARCH, 2019, 79 (04)
  • [43] Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group Study
    Karci, Ebru
    Bilici, Ahmet
    Bayram, Buket
    Celayir, Melisa
    Ozyurt, Neslihan
    Uluc, Basak Oyan
    Eken, Aynur
    Basaran, Gul
    Demirci, Umut
    Kemal, Yasemin
    Oruncu, Mehmet Berk
    Olmez, Omer Fatih
    Selcukbiricik, Fatih
    Korkmaz, Taner
    Erturk, Ismail
    Bilgetekin, Irem
    Celik, Serkan
    Turkel, Alper
    Alkan, Ali
    Sakin, Abdullah
    Can, Orcun
    Gunaldi, Meral
    Esin, Ece
    Yildiz, Ozcan
    CANCERS, 2024, 16 (19)
  • [44] Role of Neoadjuvant Chemotherapy and Surgery in T1 Triple-negative Breast Cancer Treatment: a Single-center, Retrospective Cohort Study
    Dincer, Burak
    Kaya, Cemal
    Ucak, Ramazan
    Burcu, Busra
    Sener, Aziz
    Demircioglu, Zeynep Gul
    INDIAN JOURNAL OF SURGERY, 2024,
  • [45] Anlotinib in patients with recurrent platinum-resistant or refractory ovarian carcinoma: A prospective, single-arm, single-center, phase II clinical study.
    Shan, Boer
    Shen, Wenbin
    Wang, Huaying
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [46] Anlotinib in patients with recurrent platinum-resistant or refractory ovarian carcinoma: A prospective, single-arm, single-center, phase II clinical study.
    Wang, Huaying
    Shen, Wenbin
    Shan, Boer
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [47] Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
    Schmid, P.
    Salgado, R.
    Park, Y. H.
    Munoz-Couselo, E.
    Kim, S. B.
    Sohn, J.
    Im, S. -A.
    Foukakis, T.
    Kuemmel, S.
    Dent, R.
    Yin, L.
    Wang, A.
    Tryfonidis, K.
    Karantza, V.
    Cortes, J.
    Loi, S.
    ANNALS OF ONCOLOGY, 2020, 31 (05) : 569 - 581
  • [48] Neoadjuvant chemotherapy for stage II–III breast cancer: a single-center experience
    Haidi Abd El Zaher
    Hamada Fathy
    Mohamed Abozeid
    Mohammed Faisal
    World Journal of Surgical Oncology, 21
  • [49] Receptor discordance after neoadjuvant chemotherapy with pembrolizumab in early-stage triple-negative breast cancer
    LeVee, Alexis
    Wong, Megan
    Flores, Sarah
    Ruel, Nora
    McArthur, Heather
    Waisman, James
    Mortimer, Joanne
    CANCER RESEARCH, 2024, 84 (09)
  • [50] Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI study): A prospective, single-arm, phase II trial
    Chen, Jing
    Li, Kezhen
    Hu, Yingjie
    Han, Yingyan
    Shen, Yuanming
    Wang, Yanzhou
    Song, Kun
    Xia, Bairong
    Chen, Xiaojun
    Zou, Dongling
    Wang, Yingmei
    Sun, Chaoyang
    Chen, Gang
    Ma, Ding
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345